Orexo AB (ORX) NPV

Sell:18.38 SEKBuy:18.58 SEK0.70 SEK (3.63%)

Prices delayed by at least 15 minutes
Sell:18.38 SEK
Buy:18.58 SEK
Change:0.70 SEK (3.63%)
Prices delayed by at least 15 minutes
Sell:18.38 SEK
Buy:18.58 SEK
Change:0.70 SEK (3.63%)
Prices delayed by at least 15 minutes

Company Information

About this company

Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Key people

Nikolaj Sorensen
President, Chief Executive Officer
Fredrik Jarrsten
Chief Financial Officer, Executive Vice President
Robert A. Deluca
President of Orexo US Inc.
Cecilia Coupland
Senior Vice President and Head of Operations
Robert Roenn
Senior Vice President and Head of Research and Development
Edward Kim
Chief Medical Officer
James Noble
Independent Chairman of the Board
Mary Pat Christie
Independent Director
Robin Evers
Independent Director
Charlotte Hansson
Independent Director
Staffan Lindstrand
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0000736415
  • Market cap
    SEK 669.92m
  • Employees
    110
  • Shares in issue
    34.71m
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.